Crane Harbor (CRAN): Meteora Capital discloses 6.77% Class A stake in 13G/A

Meteora Capital, LLC and managing member Vik Mittal filed an amended Schedule 13G/A for Crane Harbor Acquisition Corp. II (CRAN), reporting beneficial ownership of 2,397,812 shares of Class A common stock, or 6.77% of the class. The filing states shared voting and dispositive power over all shares and no sole control.

Original reporting
Published Aug 14, 2026, 5:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 15, 2026, 12:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CRAN
Neutral
medium confidence
Mentioned
$CRAN
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CRANNeutralLow
01

Why it matters

Traders may monitor whether additional amendments follow (e.g., stake increases, changes in intent, or voting power shifts), but the provided text alone does not indicate an active campaign or corporate action.

02

Market read

A newly disclosed 6.77% stake via Schedule 13G/A is a governance optics update, with likely limited immediate trading impact absent other catalysts.

03

What to watch

Because the filing states shared voting and shared dispositive power, the practical influence may be less than a fully controlling stake would imply.

Relevance 4/10Novelty 5/10Timing: as of the 13G/A amendment filing date (published 2026-08-14)

Background

The article summarizes a Schedule 13G/A amendment where a holder reports a substantial stake and typically claims passive, non-controlling intent.

Company-level read

Ticker impact

$CRANNeutralMedium confidence
Context

Meteora Capital filed an amended Schedule 13G/A disclosing a 6.77% Class A stake in Crane Harbor Acquisition Corp. II with shared voting and dispositive power.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven around ownership/control optics rather than cash-flow fundamentals.

Evidence & confidence

The filing provides stake size and governance power (shared), but no deal, financing, or operational change is disclosed in the text.

Market effects

Minimal, since the article is a single-company ownership disclosure without sector-wide signal.

None indicated.

None indicated.

Counterpoint

A 13G/A can reflect passive positioning, so the market may overreact to the headline stake percentage.

Key entities

  • Crane Harbor Acquisition Corp. II

    Subject of the Schedule 13G/A amendment, with Class A Common Stock stake disclosed.

  • Meteora Capital, LLC

    Reporting entity disclosing beneficial ownership of 2,397,812 shares (6.77%) of CRAN Class A.

  • Vik Mittal

    Managing member of Meteora Capital, listed as a reporting person on the filing.

Related articles

$NVDAHigh

Nvidia Reports Earnings Tuesday Without Jensen Huang for the First Time. It Promised $108 Billion, and the Stock Fell After 3 of Its Last 4 Reports

Nvidia (NVDA) will report Q3 earnings on Nov 17 without CEO Jensen Huang, who resigned. The company expects $105.84B-$110.16B revenue, with analysts forecasting $108.80B. NVDA stock fell 5.5% on Thursday, 22% below its August close. Analysts have lowered price targets post-resignation, with Stifel cutting to $205 and Baird to $200.

$BAESYMedAI 9/10

BAE Systems Wins $138 Mln U.S. Navy Submarine Contract

BAE Systems (BA.L) secured a $138M U.S. Navy contract for Virginia-class submarine propulsor assemblies, covering production, services, and parts until 2032. The company meets the Navy's annual production target and has supplied all submarines to date. Shares fell 1.36% to 1,891.50p on LSE.

$MRKMed

Merck’s Keytruda Combo Cut Melanoma Recurrence or Death Risk 42%. What the February 2 Report Has to Prove

Merck (MRK) and Moderna (MRNA) plan to file intismeran for melanoma this year, with trial data showing a 42% reduction in recurrence or death risk. Merck expects earnings guidance for 2027 on Feb. 2, with analysts forecasting flat EPS of $8.98. Keytruda, Merck's top-selling drug, faces patent expiration in 2028. Merck trades at 17.5x forward earnings, above its five-year average.

Low

BAE Systems completes Lot 8 LRASM sensor deliveries to Lockheed Martin

BAE Systems completed Lot 8 RF sensor deliveries to Lockheed Martin for the US military’s LRASM program, following investments in electronic warfare facilities. The sensors enable the missile to target ships in complex environments. BAE Systems is contracted to supply these sensors through 2028, with production expected to increase from 2026. The company also upgraded the sensor’s software to enhance capabilities.